Tikosyn Patient, Information, Instructions - Dofetilide

Tikosyn Patient, Information, Instructions - Dofetilide INFORMATION FOR PATIENTS

Please refer patient to the patient package insert.

Prior to initiation of TIKOSYN therapy, the patient should be advised to read the patient package insert and reread it each time therapy is renewed in case the patient's status has changed. The patient should be fully instructed on the need for compliance with the recommended dosing of TIKOSYN and the potential for drug interactions, and the need for periodic monitoring of QTc and renal function to minimize the risk of serious abnormal rhythms.

Medications and Supplements:   Assessment of patients' medication history should include all over-the-counter, prescription and herbal/natural preparations with emphasis on preparations that may affect the pharmacokinetics of TIKOSYN such as cimetidine (see CONTRAINDICATIONS ), trimethoprim alone or in combination with sulfamethoxazole (see CONTRAINDICATIONS ), prochlorperazine (see CONTRAINDICATIONS ), megestrol (see CONTRAINDICATIONS ), ketoconazole (see CONTRAINDICATIONS ), other cardiovascular drugs (especially verapamil see CONTRAINDICATIONS ), phenothiazines, and tricyclic antidepressants (see WARNINGS). If a patient is taking TIKOSYN and requires anti-ulcer therapy, omeprazole, ranitidine or antacids (aluminum and magnesium hydroxides) should be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetics of TIKOSYN. Patients should be instructed to notify their health care providers of any change in over-the-counter, prescription or supplement use. If a patient is hospitalized or is prescribed a new medication for any condition, the patient must inform the health care provider of ongoing TIKOSYN therapy. Patients should also check with their health care provider and/or pharmacist prior to taking a new over-the-counter preparation.

Electrolyte Imbalance:   If patients experience symptoms that may be associated with altered electrolyte balance, such as excessive or prolonged diarrhea, sweating, or vomiting or loss of appetite or thirst, these conditions should immediately be reported to their health care provider.

Dosing Schedule:   Patients should be instructed NOT to double the next dose if a dose is missed. The next dose should be taken at the usual time.